Table 1.
Liquid biopsy variables according to patient baseline demographic and clinical characteristics.
| Baseline Characteristics | All | CTC+ve | CTC−ve | p | AR+ve | AR−ve | p | ARv7+ve | ARv7−ve | p | CTC+ve/ARv7+ve | CTC+ve/ARv7−ve | p |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | 37 | 21 | 16 | / | 17 | 20 | / | 9 | 28 | 9 | 12 | ||
| Age | 75.3 | 75.3 | 74.6 | 0.37 | 75.1 | 76.6 | 0.84 | 78.5 | 75.1 | 0.64 | 78.5 | 75.1 | 0.97 |
| Months since diagnosis of metastatic castration-resistant prostate cancer (mCRPC) | 0.73 | 1.27 | 0.57 | 0.365 | 1.58 | 0.47 | 0.13 | 2.5 | 0.72 | 0.97 | 2.5 | 1.0 | 0.80 |
| Gleason sum at diagnosis | 0.04 | 0.40 | 0.25 | 0.08 | |||||||||
| ≤7 | 9 | 1 | 8 | 2 | 7 | 0 | 9 | 0 | 1 | ||||
| ≥8 | 14 | 8 | 6 | 6 | 8 | 3 | 11 | 3 | 5 | ||||
| NA | 14 | ||||||||||||
| Metastases at diagnosis | 0.73 | 0.47 | 0.50 | 0.31 | |||||||||
| Bone | 21 | 13 | 8 | 11 | 10 | 6 | 15 | 6 | 7 | ||||
| Viscera | 5 | 3 | 2 | 1 | 4 | 0 | 5 | 0 | 3 | ||||
| Bone+viscera | 11 | 5 | 6 | 6 | 5 | 3 | 8 | 3 | 2 | ||||
| Local treatment | 0.005 | 0.009 | 0.295 | 1.00 | |||||||||
| Surgery | 13 | 4 | 9 | 4 | 9 | 2 | 11 | 2 | 2 | ||||
| RT1 | 4 | 1 | 3 | 0 | 4 | 0 | 4 | 0 | 1 | ||||
| None | 20 | 16 | 4 | 14 | 6 | 7 | 13 | 7 | 9 | ||||
| Basal PSA | 0.09 | 0.02 | 0.21 | 0.85 | |||||||||
| ≤18 | 12 | 4 | 8 | 3 | 9 | 1 | 11 | 1 | 3 | ||||
| 18–63 | 12 | 7 | 5 | 4 | 8 | 3 | 9 | 3 | 4 | ||||
| ≥63 | 13 | 10 | 3 | 10 | 3 | 5 | 8 | 5 | 5 | ||||
| Systemic treatment | 0.28 | 0.29 | 1.0 | 1.0 | |||||||||
| Abiraterone | 26 | 13 | 13 | 11 | 15 | 6 | 20 | 6 | 7 | ||||
| Enzalutamide | 11 | 8 | 3 | 7 | 4 | 3 | 8 | 3 | 5 |
1 Radiotherapy.